REHOVOT, Israel and NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that Steve Lisi, Chief Executive Officer, will provide a corporate overview at the 30th Annual ROTH Conference, and the 28th Annual Oppenheimer Healthcare Conference.

30th Annual ROTH Conference
Date:  Monday, March 12
Time: 8:30am Pacific Time/11:30am Eastern Time
Location: Ritz Carlton, Laguna Niguel, California - BLUE Track - Salon 2
Webcast: http://wsw.com/webcast/roth32/aitb/
   
Oppenheimer 28th Annual Healthcare Conference
Date: Tuesday, March 20
Time: 4:30pm Eastern Time
Location: Westin Grand Central Hotel, Track 3

About AIT Therapeutics Inc. 
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension.  The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care.  AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM).  For more information, visit www.AIT-Pharm.com.

CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
Steve@AIT-Pharm.com

Bob Yedid
LifeSci Advisors, LLC
Bob@LifeSciAdvisors.com
(646) 597 6989